Figure 2.

CCL2 blockade inhibited spontaneous metastases in a model of NSCLC. LKR-M flank tumors were allowed to reach an average size of 200–250 mm³. Mice were then treated with either saline (Control) or intraperitoneal α-CCL2/CCL12 mAbs twice weekly (a-CCL2). After 5 or 6 weeks of treatment, mice were evaluated for lung metastases. (A) Macroscopic (top) and hematoxylin-and-eosin–stained section (bottom) of lungs from control or a-CCL2–treated mice. (B and C) Changes in lung weight compared with lungs from naive mice (B), and the percentages of lung occupied by metastases (C) in each group, showed a significant reduction in tumor burden in mice treated with a-CCL2. (D) Number of nodules in each of the two groups at 6 weeks. No significant difference was evident in the number of nodules. (B–D) Each dot represents one mouse. *P < 0.05.